Rigel Pharmaceuticals Inc（RIGL）の財務RIGLRigel Pharmaceuticals Inc

Evaluating the bottom line, Rigel Pharmaceuticals, Inc. maintains a gross margin of 89.17%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 29.95%, while the net margin is 21.97%. These profitability ratios, combined with a Return on Equity (ROE) of 126.90%, provide a clear picture of how effectively RIGL converts its operational activities into shareholder value.

In the context of the broader market, RIGL competes directly with industry leaders such as ALMS and CRVS. With a market capitalization of $858.71M, it holds a significant position in the sector. When comparing efficiency, RIGL's gross margin of 89.17% stands against ALMS's 100.00% and CRVS's N/A. Such benchmarking helps identify whether Rigel Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Rigel reported total revenues of $78.7 million in Q2 2026, with net income of $17.29 million, reflecting strong financial performance and growth in its oncology and hematology segments.